Preclinical and early-phase clinical studies further show that CCL21-DCs tumor-lysate vaccines can augment anti-PD-1 activity, underscoring the broader potential of modulating TLS-associated chemokines [86,88,89,90,91]. This evidence concerns the gene PDCD1 and neoplasm.